Form 4: Arvinas CFO Andrew Saik Receives Stock Options and Restricted Stock Units

Andrew Saik, CFO of Arvinas, Inc., was granted stock options and restricted stock units (RSUs) on June 24, 2024, as part of an incentive plan.

Summary

• On June 24, 2024, Andrew Saik, the Chief Financial Officer of Arvinas, Inc., received 94,418 stock options with an exercise price of $24.97.
• These options were granted outside of the company's 2018 Stock Incentive Plan, in accordance with Nasdaq Listing Rule 5635(c)(4).
• The options vest over four years, with 1/4 vesting on June 24, 2025, and the remainder in equal monthly installments until June 24, 2028.
• Saik also received 61,409 restricted stock units (RSUs) on the same date, also outside the 2018 Stock Incentive Plan, in accordance with Nasdaq Listing Rule 5635(c)(4).
• Each RSU represents the right to receive one share of Arvinas' common stock upon settlement.
• The RSUs vest over four years, with 25% vesting annually on June 24, from 2025 to 2028, contingent upon continued service with the company.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management's interests with shareholders. The sentiment is neutral to slightly positive.

Positives

• The grant of stock options and RSUs to the CFO aligns his interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the CFO.

Future Outlook

The vesting schedules for the options and RSUs are designed to incentivize the CFO's continued service and contribution to the company's long-term success.

Industry Context

Granting stock options and RSUs is a common practice in the biotechnology industry to attract and retain key executives, aligning their interests with those of shareholders and incentivizing long-term value creation.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotech industry, often benchmarked against peer companies of similar size and stage of development.
• Companies like Amgen, Gilead, and Biogen also utilize stock options and RSUs as part of their executive compensation plans to incentivize performance and retention.
• The vesting schedules are fairly standard, with four-year vesting periods being common in the industry.

Stakeholder Impact

• Shareholders may view the grant of stock options and RSUs positively, as it incentivizes the CFO to drive long-term value creation.
• Employees may see this as a positive sign of the company's commitment to its leadership team.

Key Dates